文献速递冠心病

人冠状动脉血管舒张功能可预测未来冠状动脉粥样硬化进展

Evaluation of human coronary vasodilator function predicts future coronary atheroma progression.
PubMed 文献 · Heart · 2018-03-01

本研究纳入33例稳定胸痛或急性冠脉综合征患者,采用系列冠状动脉血管舒张功能评估及血管内超声和近红外光谱成像,随访12-18个月(520个节段)。结果显示基线内皮依赖性及非依赖性舒张功能受损与未来脂质斑块出现相关,内皮依赖性功能预测LCBI变化,非依赖性功能预测PAV变化。

要点

  • 冠状动脉血管舒张功能受损可预测未来斑块进展和脂质负荷增加。
  • 内皮依赖性功能预测LCBI变化,非依赖性功能预测PAV变化。
  • 基线无脂质节段未来出现脂质斑块者基线舒张功能更差。

核心结论

  • 心外膜冠状动脉血管舒张功能是未来粥样硬化进展和组成的决定因素,与临床表现类型无关。

研究设计与样本

  • 前瞻性队列研究,纳入33例稳定胸痛或急性冠脉综合征患者,系列评估冠状动脉血管舒张功能及IVUS和NIRS成像,随访12-18个月,共520个节段。

主要发现

  • 基线无脂质而随访出现脂质斑块的节段,基线内皮依赖性功能为-0.24±2.96 vs 5.60±1.47%,P=0.04;内皮非依赖性功能为13.91±4.45 vs 21.19±3.19%,P=0.036。
  • 多因素分析显示内皮依赖性功能预测∆LCBI(β=-3.03,95%CI -5.81至-0.25,P=0.033),内皮非依赖性功能预测∆PAV(β=0.07,95%CI 0.04至0.10,P<0.0001)。

临床怎么用

  • 冠状动脉血管舒张功能评估可能有助于识别未来斑块进展和脂质负荷增加的高危患者。

局限性

  • 样本量较小(33例患者),随访时间12-18个月,需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Coronary vasodilator function and atherosclerotic plaque progression have both been shown to be associated with adverse cardiovascular events. However, the relationship between these factors and the lipid burden of coronary plaque remains unknown. These experiments focus on investigating the relationship between impaired coronary vasodilator function (endothelium dependent (salbutamol) and endothelium independent (glyceryl trinitrate)) and the natural history of atheroma plaque progression and lipid burden using dual modality intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) imaging. METHODS: 33 patients with stable chest pain or acute coronary syndrome underwent serial assessment of coronary vasodilator function and intracoronary plaque IVUS and NIRS imaging. Coronary segmental macrovascular response (% change segmental lumen volume (ΔSLV)), plaque burden (per cent atheroma volume (PAV)), lipid core (lipid-rich plaque (LRP) and lipid core burden index (LCBI)) were measured at baseline and after an interval of 12-18 months (n=520 segments). RESULTS: Lipid-negative coronary segments which develop into LRP over the study time period demonstrated impaired endothelial-dependent function (-0.24±2.96 vs 5.60±1.47%, P=0.04) and endothelial-independent function (13.91±4.45 vs 21.19±3.19%, P=0.036), at baseline. By multivariate analysis, endothelial-dependent function predicted ∆LCBI (β coefficient: -3.03, 95% CI (-5.81 to -0.25), P=0.033) whereas endothelial-independent function predicted ∆PAV (β coefficient: 0.07, 95% CI (0.04 to 0.10), P<0.0001). CONCLUSIONS: Epicardial coronary vasodilator function is a determinant of future atheroma progression and composition irrespective of the nature of clinical presentation. TRIAL REGISTRATION NUMBER: ACTRN12612000594820, Post-results.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Sidharta SL, Baillie TJ, Howell S, et al. Evaluation of human coronary vasodilator function predicts future coronary atheroma progression. Heart. 2018. PMID: 29496901. doi:10.1136/heartjnl-2017-312579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。